1. Pink Sheet
  2. >>Market Access

Louisiana Subscription Contract For Generic Epclusa About Access, Not Discounts

 
• By Cathy Kelly

Innovative purchasing model is not designed to solve the problem of high drug costs, experts point out during a recent discussion at the Brookings Institution.

Subscription vs One-Time Payment - Traffic sign with two options - subscribe periodical service and product vs singular purchase and payment. - Image
Subscription Model Might Also Work For Sickle Cell, Hemophilia Treatments

 The state of Louisiana’s innovative subscription purchasing model for the authorized generic version of Gilead Sciences Inc.’s hepatitis C drug Epclusa is primarily designed to ensure patient access to the treatment and not necessarily to lower state spending on the drug.

“The pitch was always this: it was never about just a slightly better price or a better deal,” Louisiana Department of Health Secretary Rebekah Gee told the Brookings Institution on 22 July. “It was that … we have a cure

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

HHS Negotiating With Manufacturers On Most Favored Nation Drug Pricing

 
• By Cathy Kelly

HHS released the parameters for the MFN policy, which would would apply to all single source drugs in all insurance markets, according to HHS release. Secretary Robert F. Kennedy Jr. said the department is discussing the plan with drug sponsors.

Spain Slashes Wait Between EU Drug Authorization And Financing Decisions

 
• By Francesca Bruce

Spanish authorities say that that timelines for drug reimbursement decisions can be improved further with the right submissions from companies.

Spain Beats England To Tevimbra Reimbursement Recommendations

 
• By Francesca Bruce

Spanish authorities have published more pricing and reimbursement reports as part of a new drive to increase transparency.

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By Tim Casey

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.

More from Pink Sheet

Commission Taking ‘Due Account’ Of Scathing Report On EU Clinical Trial Bottlenecks

 
• By Vibha Sharma

A report by the European pharmaceutical industry criticizes the EU’s clinical trials framework, highlighting regulatory fragmentation, inefficiencies and the need for targeted reforms.

UK MHRA’s Clinical Trial Lead On Combined Reviews, The Notification Scheme & Increasing Diversity

 
• By Eliza Slawther

In light of the UK’s MHRA announcing a major overhaul of its clinical trial legislation, the agency’s deputy director for clinical investigations and trials Andrea Manfrin tells the Pink Sheet what sponsors can expect from the new regulation.

Novavax’s COVID-19 Vaccine Label Narrowed After Political Officials Intervened

 
• By Sarah Karlin-Smith

The label that Novavax's COVID-19 vaccine was slated to receive before political officials held up the approval was broader than was granted 16 May.